Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Posted: Wednesday, September 27, 2017

Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.